Research profile
Growth-hormone signalling and adipose tissue
Disease-specific human trials
What it is and why it is studied
Tesamorelin research examines the connection between growth-hormone-releasing hormone activity and fat distribution. Particular attention has been given to visceral fat, the fat within the abdominal cavity, in a defined clinical setting.
What studies have found
Trials in people with HIV-associated abdominal fat accumulation reported reductions in visceral fat. A smaller trial also reported reduced liver fat and a transient rise in fasting glucose. In the longer trial, visceral-fat improvements were lost after treatment was withdrawn.
These studies concern a specific clinical population and medicinal preparation. They do not establish general body-composition benefits or suitability of this research vial for people.
Read the research
Chemical reference
| Molecular formula | C221H366N72O67S |
|---|---|
| Molar mass | Approximately 5136 g/mol |
| Reference CAS | 218949-48-5 |
| PubChem CID | 16137828 |
Chemical information describes the named reference structure, not a batch analysis or confirmation of the material supplied. Counterions, water and excipients are excluded unless stated.
Understanding these details
A sequence describes the order of residues in a peptide. A molecular formula describes the atoms in the reference structure. Molar mass is expressed in grams per mole; it is not the amount in a vial. CAS numbers and PubChem identifiers help you find the corresponding chemical records.
Selected literature and reference information checked 11 September 2026. Study findings concern the preparations and models described; they do not certify this product. For laboratory research only.
Reviews
There are no reviews yet.